Immix Biopharma annual stock-based compensation
2021
2022
2023
2024
2025
Immix Biopharma Stock-Based Compensation Growth & History (IMMX)
Immix Biopharma's stock-based compensation was $2.4M for fiscal 2025.
View full Immix Biopharma company overviewImmix Biopharma annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $2.4M | −$578,698 | −19.16% |
| 2024 | 2024-12-31 | $3.0M | $454,865 | +17.73% |
| 2023 | 2023-12-31 | $2.6M | $1.9M | +311.13% |
| 2022 | 2022-12-31 | $624,069 | $405,086 | +184.99% |
| 2021 | 2021-12-31 | $218,983 | — | — |
Immix Biopharma quarterly stock-based compensation
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $978,140 | $445,891 | +83.77% |
| Q1 2026 | 2026-03-31 | $575,565 | −$292,794 | −33.72% |
| Q4 2025 | 2025-12-31 | $570,796 | −$134,857 | −19.11% |
| Q3 2025 | 2025-09-30 | $470,471 | −$263,335 | −35.89% |
| Q2 2025 | 2025-06-30 | $532,249 | −$105,601 | −16.56% |
| Q1 2025 | 2025-03-31 | $868,359 | −$74,905 | −7.94% |
| Q4 2024 | 2024-12-31 | $705,653 | −$345,155 | −32.85% |
| Q3 2024 | 2024-09-30 | $733,806 | −$3,519 | −0.48% |
| Q2 2024 | 2024-06-30 | $637,850 | $190,194 | +42.49% |
| Q1 2024 | 2024-03-31 | $943,264 | $613,345 | +185.91% |
| Q4 2023 | 2023-12-31 | $1.1M | $820,714 | +356.69% |
| Q3 2023 | 2023-09-30 | $737,325 | $524,133 | +245.85% |
| Q2 2023 | 2023-06-30 | $447,656 | $331,947 | +286.88% |
| Q1 2023 | 2023-03-31 | $329,919 | $264,845 | +406.99% |
| Q4 2022 | 2022-12-31 | $230,094 | $107,942 | +88.37% |
| Q3 2022 | 2022-09-30 | $213,192 | $151,332 | +244.64% |
| Q2 2022 | 2022-06-30 | $115,709 | $84,985 | +276.61% |
| Q1 2022 | 2022-03-31 | $65,074 | $60,827 | +1432.23% |
| Q4 2021 | 2021-12-31 | $122,152 | — | — |
| Q3 2021 | 2021-09-30 | $61,860 | — | — |
| Q2 2021 | 2021-06-30 | $30,724 | — | — |
| Q1 2021 | 2021-03-31 | $4,247 | — | — |
Immix Biopharma stock-based compensation trends
Between the periods ended 2021-12-31 and 2025-12-31, Immix Biopharma's stock-based compensation increased from $218,983 to $2.4M, a change of $2.2M. The latest reported quarter, Q2 2026, shows $978,140.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Immix Biopharma source filings ↗